ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The subclone of leukemia cells carrying imatinib-resistant mutations in the kinase domain of BCR-ABL can cause CML patients to relapse after receiving imatinib treatment (Charles, 2012; Wilting and Dannenberg, 2012).